Table 2 Characteristics of CAPA cohort

Days from SARS-CoV-2 infection to diagnosis of CAPA, median (IQR)

17 (12–31)

Days from clinical worsening to diagnosis of CAPA, median (IQR)

3 (0–6)

Days to diagnosis of CAPA to death, median (IQR)

6 (4–15)

Post-mortem diagnosis, n (%)

5 (9.1)

PaO₂/FiO₂ ratio at diagnosis of CAPA, median (IQR)

127 (88.5–200.8)

Classification of CAPA

 Proven, n (%)

0 (0)

 Probable, n (%)

18 (32.7)

 Possible, n (%)

37 (67.3)

Respiratory treatment at diagnosis of CAPA

 Venturi Mask, n (%)

15 (27.3)

 HFNC, n (%)

23 (41.8)

 Helmet CPAP, n (%)

6 (10.9)

 NIV, n (%)

6 (10.9)

Clinical criteria

 Fever, n (%)

13 (23.6)

 Worsening respiratory failure, n (%)

52 (94.5)

 Haemoptisis, n (%)

6 (10.9)

Radiological criteria^a

n = 28

 Lung infiltrates, n (%)

25 (89.3)

 Cavitations, n (%)

1 (3.6)

 Nodules, n (%)

6 (21.4)

Microbiological criteria

 Aspergillus spp growth, n (%)

15 (27.3)

 Respiratory samples Galactomannan index, median (IQR)^b

3.75 (1.9–6.5)

 Serum Galactomannan index, median (IQR)^c

1.45 (0.75–3.97)

Antifungal therapy^d

n = 50

 Voriconazole, n (%)

4 (8.0)

 Isavuconazole, n (%)

40 (80.0)

 Amphotericin B, n (%)

6 (12.0)